Blockchain Registration Transaction Record
TransCode Therapeutics to Host First Live R&D Webcast on June 18, 2026
TransCode Therapeutics announces first live R&D webcast on June 18, 2026, highlighting Phase 2a trial of TTX-MC138 in colorectal cancer. Learn about updates to its RNA therapy pipeline.
This news matters because it provides a window into TransCode's progress with TTX-MC138, a novel RNA therapeutic targeting metastatic cancer. For investors and patients, the Phase 2a trial results could signal a breakthrough in treating colorectal cancer and other aggressive tumors. The webcast offers transparency and insight into the company's strategy and pipeline, which could influence investment decisions and patient hope for new treatments.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x49733140985d1a944cf7b72d1473930c706eb07100bbb5a25a4b52a154125ace |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | wamciO7B-5a0742afbf9d6178230e1da7cfe1a698 |